Since
2021
United Kingdom
Data processing
TRL 4

Challenge

CTA requires contrast unless you can see without it.

If the patient journey requires a CTA to view and or track an aortic aneurysm, the IV contrast can be associated with problems such as patient discomfort, allergic reactions, anaphylaxis, kidney injury, etc. along with a second CT scan adding to the radiation dosing.

 

Opportunity

Our value proposition lies in its ability to replace existing CTA contrast technology with next-generation vascular imaging technology, providing a patient-first approach to arterial studies. AiSentia’s technology eliminates the need for harmful contrast agents, patient IV discomfort, and unnecessary radiation dosing while seamlessly integrating into the current clinical workflow. It allows patients with contrast-induced nephropathy (CIN), renal failure, or anaphylactic reaction to contrast access to CTA scans which roughly represent 2% of the population.

Solution

AiSentia can see more than the human eye! Our deep learning driven AI pipelines harness additional information from routine CT scans performed without intravenous contrast injection.

Status

The current top priorities are to start the funding process, to prepare steps for FDA (pre-submission meeting), to identify an American clinical validation partner, and to identify a prototype SW development partner.

Meet the team

Paul Unkel

Paul Unkel

CEO

Marcel

Marcel Wassink

Venture Partner NLC

Entrepreneur with more than 30 years experience in building global businesses, developing and executing growth strategies mainly in healthcare including mergers and acquisitions. Built businesses within corporates (Fujitsu, Philips Speech Processing,  Nuance Communications) as well as through co-founding or investing in start-ups such as Superevent, Telecats Austria, ESR iGuide, contextflow and NLC.